Development and characterization of functionalized niosomes for brain targeting of dynorphin-B.

A niosomal formulation, functionalized with N-palmitoylglucosamine, was developed as potential brain targeted delivery system of dynorphin-B. In fact, this endogenous neuropeptide, selective agonist of k opioid receptors, is endowed with relevant pharmacological activities on the central nervous system, including a marked antinociceptive effect, but is unable to cross the blood brain barrier (BBB), thus requiring intracerebroventricular administration. Statistical design of experiments was utilized for a systematic evaluation of the influence of variations of the relative amounts of the components of the vesicle membrane (Span 60, cholesterol and SolulanC24) on vesicle mean diameter, polydispersity index and drug entrapment efficiency, chosen as the responses to optimize. A Scheffé simplex-centroid design was used to obtain the coefficients of the postulated mathematical model. The study of the response surface plots revealed that variations of the considered factors had different effects on the selected responses. The desirability function enabled for finding the optimal mixture composition, which represented the best compromise to simultaneously optimize all the three responses. The experimental values obtained with the optimized formulation were very similar to the predicted ones, proving the validity of the proposed regression model. The optimized niosomal formulation of dynorphin-B administered intravenously to mice (100mg/kg) showed a pronounced antinociceptive effect, significantly higher (P<0.05) than that given by i.v. administration of the simple solution of the peptide at the same concentration, proving its effectiveness in enabling the peptide brain delivery. These positive results suggest that the proposed approach could be successfully extended to other neuro-active peptides exerting a strong central action, even at low doses, but unable to cross the BBB.

[1]  Wen-Yih Chen,et al.  Microcalorimetric and shear studies on the effects of cholesterol on the physical stability of lipid vesicles , 2000 .

[2]  Uchiyama,et al.  The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. , 1999, Advanced drug delivery reviews.

[3]  S Furlanetto,et al.  Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-β-cyclodextrin-PVP complex. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  N. Hayward,et al.  Neuroprotective actions of GR89696, a highly potent and selective κ‐opioid receptor agonist , 1991 .

[5]  Dora Brites,et al.  Looking at the blood–brain barrier: Molecular anatomy and possible investigation approaches , 2010, Brain Research Reviews.

[6]  R. Spealman,et al.  Opioid modulation of the discriminative stimulus effects of cocaine: comparison of µ, kappa and delta agonists in squirrel monkeys discriminating low doses of cocaine. , 1994, Behavioural pharmacology.

[7]  S. Furlanetto,et al.  Study of formulation variables influencing the drug release rate from matrix tablets by experimental design. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  C. Ghelardini,et al.  Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. , 2012, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[9]  R. Duncan,et al.  Niosomes containing N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin (PK1) : effect of method of preparation and choice of surfactant on niosome characteristics and a preliminary study of body distribution , 1997 .

[10]  Roger Phan-Tan-Luu,et al.  Pharmaceutical Experimental Design , 1998 .

[11]  Mayur M. Patel,et al.  Getting into the Brain , 2009, CNS Drugs.

[12]  H. Davson,et al.  Kinetic Analysis of Leucine‐Enkephalin Cellular Uptake at the Luminal Side of the Blood‐Brain Barrier of an In Situ Perfused Guinea‐Pig Brain , 1989, Journal of neurochemistry.

[13]  Sandra Furlanetto,et al.  Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. , 2002, International journal of pharmaceutics.

[14]  D. Craig,et al.  The effect of processing variables on the physical characteristics of non-ionic surfactant vesicles (niosomes) formed from a hexadecyl diglycerol ether. , 2000, International journal of pharmaceutics.

[15]  D. Singodia,et al.  Excipient Selection In Parenteral Formulation Development , 2013 .

[16]  S. Furlanetto,et al.  Response surface methodology in the optimization of chitosan-Ca pectinate bead formulations. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  James K Drennen,et al.  Performance-based quality specifications: the relationship between process critical control parameters, critical quality attributes, and clinical performance. , 2011, Journal of pharmaceutical sciences.

[18]  F. Rinaldi,et al.  Niosomes from 80s to present: the state of the art. , 2014, Advances in colloid and interface science.

[19]  L. Tetley,et al.  Niosomes and Polymeric Chitosan Based Vesicles Bearing Transferrin and Glucose Ligands for Drug Targeting , 2000, Pharmaceutical Research.

[20]  G. Pasternak,et al.  Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector-Mediated Strategy , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  Jing Qin,et al.  Surface modification of RGD-liposomes for selective drug delivery to monocytes/neutrophils in brain. , 2007, Chemical & pharmaceutical bulletin.

[22]  S Furlanetto,et al.  Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design. , 2005, Journal of pharmaceutical and biomedical analysis.

[23]  D. A. Kharkevich,et al.  Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles , 1997, Pharmaceutical Research.

[24]  V. Sankar,et al.  NIOSOME DRUG DELIVERY SYSTEM: ADVANCES AND MEDICAL APPLICATIONS - AN OVERVIEW , 2009 .

[25]  R. Spealman,et al.  Opioid modulation of the discriminative stimulus effects of cocaine: comparison of μ, k and δ agonists in squirrel monkeys discriminating low doses of cocaine , 1994 .

[26]  A. Schätzlein,et al.  Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. , 2004, International journal of pharmaceutics.

[27]  D. V. Kohli,et al.  Transferrin coupled liposomes as drug delivery carriers for brain targeting of 5-florouracil , 2005, Journal of drug targeting.

[28]  G. Golomb,et al.  Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[29]  A. Pardakhty,et al.  Nano-niosomes in drug, vaccine and gene delivery: a rapid overview , 2013 .

[30]  A. Schätzlein,et al.  Anticancer Drug Delivery with Transferrin Targeted Polymeric Chitosan Vesicles , 2004, Pharmaceutical Research.

[31]  J. Álvarez-Fuentes,et al.  Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. , 2002, International journal of pharmaceutics.

[32]  D. Begley,et al.  Direct Evidence That Polysorbate-80-Coated Poly(Butylcyanoacrylate) Nanoparticles Deliver Drugs to the CNS via Specific Mechanisms Requiring Prior Binding of Drug to the Nanoparticles , 2003, Pharmaceutical Research.

[33]  L. Brady,et al.  Analgesic effects of intraventricular morphine and enkephalins in nondependent and morphine-dependent rats. , 1982, The Journal of pharmacology and experimental therapeutics.

[34]  N. Mello,et al.  Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. , 2000, Pharmaceutica acta Helvetiae.

[35]  W. Pardridge The blood-brain barrier: Bottleneck in brain drug development , 2005, NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics.

[36]  M. Adler,et al.  Antinociceptive action of intracerebroventricularly administered dynorphin and other opioid peptides in the rat. , 1988, The Journal of pharmacology and experimental therapeutics.

[37]  F. Szoka,et al.  Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating , 2005, Brain Research.

[38]  W. Pardridge Molecular Regulation of Blood-Brain Barrier GLUT1 Glucose Transporter , 1995 .

[39]  S. Welch,et al.  Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. , 1997, The Journal of pharmacology and experimental therapeutics.

[40]  I. Uchegbu,et al.  Vesicles prepared from synthetic amphiphiles — polymeric vesicles and niosomes , 2006 .

[41]  W. Pardridge,et al.  Blood-brain barrier delivery. , 2007, Drug discovery today.

[42]  R. Koehler,et al.  Neuroprotective Effect of Selective Kappa Opioid Receptor Agonist is Gender Specific and Linked to Reduced Neuronal Nitric Oxide , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  R. Imberti,et al.  Drug delivery to the central nervous system , 2010 .

[44]  Ijeoma F. Uchegbu,et al.  Non-ionic surfactant based vesicles (niosomes) in drug delivery , 1998 .

[45]  Hideyoshi Harashima,et al.  Enhanced Hepatic Uptake of Liposomes Through Complement Activation Depending on the Size of Liposomes , 1994, Pharmaceutical Research.

[46]  Jean-Pierre Benoit,et al.  Active targeting of brain tumors using nanocarriers. , 2007, Biomaterials.

[47]  B. Sabel,et al.  Efficacy of Oral Dalargin-loaded Nanoparticle Delivery across the Blood–Brain Barrier , 1998, Peptides.

[48]  P. Couvreur,et al.  Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? , 2005, International journal of pharmaceutics.

[49]  D. Aggarwal,et al.  Vesicular systems in ocular drug delivery: an overview. , 2004, International journal of pharmaceutics.